- Tuesday
Globally, one out of 100 children is born with a heart defect. Repeated surgery and lifelong medical treatment is often required, as the missing or damaged part of the heart is commonly replaced by artificial prosthetic materials without growth and regeneration capacity. As a consequence, current treatment modalities are associated with substantial morbidity and mortality. The project “LifeMatrix”, supported by the Wyss Translational Center Zurich, aims at the clinical translation of a novel, “off-the-shelf”, tissue engineered human matrix technology with growth and regeneration capacity for the treatment of children with congenital heart disease.
Join us at the Royal Society of Medicine for a presentation and discussion with leading experts from Imperial College London and University of Zurich on this specific project and the challenges of clinical translation in regenerative medicine.
SCHEDULE
15.30 Registration
16.00 Welcome (Sir Magdi Yacoub)
16.05 The Wyss Translational Center Zurich (Michael Stucky, COO Wyss Zurich)
16.25 Translation in Regenerative Medicine – The LifeMatrix Project (Prof. Simon P. Hoerstrup, MD, PhD, Director of the Institute of Regenerative Medicine, University of Zurich and Founding Co-Director of Wyss Zurich)
16.45 The Saw Device (Chris Mcleod, Principal Research Fellow, Imperial College London)
17.00 NO eluting Nanopraticles for PAH (Adrian Chester, Honorary Senior Fellow, Imperial College London)
17.15 Taking Cardiac Surgery to the People (Sir Magdi Yacoub, Professor of Cardiothoracic Surgery, Imperial College London)
17.35 Panel Discussion
17.45 Drinks Reception in The Atrium